COMPOUND PROFILE / PEPTIDES & ANALOGUES
VK2735.
Research draftVK2735 is a dual GIP and GLP-1 receptor agonist investigated for obesity.
Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.
Targeted source and identity review, not a systematic review or complete regulatory audit.
Overview
VK2735 is a dual GIP and GLP-1 receptor agonist investigated for obesity.
Mechanism
It combines incretin pathways affecting appetite and glucose regulation.
Human research
The randomised subcutaneous VENTURE study provides phase 2 evidence. Oral formulation development must be assessed separately.
Preclinical & other research
Receptor and metabolic studies informed development.
Safety & unknowns
Gastrointestinal symptoms and limited long-term exposure are relevant.
Regulatory status
Investigational; oral and injectable versions are not interchangeable evidence.
Reported use & evidence
The supplied VK2735 profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.
Sources & references
Follow the cited records and registered research. Profiles remain research drafts.